Addressing the
COVID-19
workflow challenge
A comprehensive, multidisciplinary
workflow solution
siemens-healthineers.com
The coronavirus (SARS-CoV-2) pan-
demic continues to confront health-
care professionals around the world
with unprecedented clinical and op-
erational challenges. To effectively
diagnose and treat the many clinical
complications that often accompany
a COVID-19 diagnosis, labs need a
comprehensive workflow solution to
optimize testing for the detection,
prognosis, treatment, and follow-up
of COVID-19 patients.
SARS-CoV-2 Total Assay
The SARS-CoV-2 Total (COV2T) Assay detects
both IgM and longer-lasting IgG antibodies
with high sensitivity for recent and prior
infection. COV2T specifically detects anti-
bodies that recognize the part of the virus,
called the receptor binding domain (RBD),
that binds to the host human cell.
SARS-CoV-2 IgG Assay
With recovery, IgM antibodies disappear
while IgG to SARS-CoV-2 antibodies
remain for a period of time. The
SARS-CoV-2 IgG (COV2G) Assay specifically
identifies IgG to the RBD, and may indicate
some level of protection. Antibodies to the
RBD are a focus of several vaccines in
development. Should these vaccines prove
efficacious, testing for the RBD IgG could
help identify those who have antibodies
from a recovered infection versus those
likely to more immediately benefit from
vaccination.
